Lung cancer therapeutics market size to grow by USD 10,204.33 million: High prevalence of lung cancer remains key growth driver – Technavio

NEW YORK, Dec. 8, 2022 /PRNewswire/ — The global lung cancer therapeutics market size is expected to grow by USD 10,204.33 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 7.92% during the forecast period. This report provides analysis and insights to enable effective decision-making. Download a sample report

Lung Cancer Therapeutics Market – Key Driver and Major Challenge

The high prevalence of lung cancer is driving the lung cancer therapeutics market growth. The number of new cases of lung cancer has increased significantly in recent years due to factors such as the growth of the geriatric population and changing lifestyles. As a result, the number of patients undergoing treatments such as immunotherapy and chemotherapy for lung cancer has also increased. Moreover, there are advanced therapeutics in the pipeline with proven efficacy, which is leading to quick approvals in clinical stages. Therefore, owing to the high incidence of the disease and the increasing drug approvals, the market is expected to grow during the forecast period.

Adherence to available alternatives is impeding the lung cancer therapeutics market growth. Therapeutics are not highly effective during the early stages of lung cancer. Hence, surgery and radiation therapy are the most-preferred treatment options. Factors such as technological advances in radiation therapy are also challenging the growth of the market. In addition, advances in diagnostic methods for the detection of lung cancer pose a threat to the growth of the market. Thus, advances in early detection of lung cancer and the increasing use of surgeries and radiation therapy for treatment are expected to impede the growth of the market during the forecast period.

Technavio has identified key trends, drivers, and challenges, along with competitive
analysis, to help clients improve their strategies to stay ahead of their competitors. Buy
the report to obtain detailed insights about the market.

Major Five Lung Cancer Therapeutics Companies

• AbbVie Inc. – The company offers lung cancer therapeutics, namely Teliso-V.
• Amgen Inc. – The company offers lung cancer therapeutics, namely Lumakras.
• Astellas Pharma Inc. – The company offers lung cancer therapeutics, namely Tarceva.
• AstraZeneca Plc – The company offers lung cancer therapeutics, namely Tagrisso.
• Bristol Myers Squibb Co. – The company offers lung cancer therapeutics, namely Giotrif.

Other key vendors

• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• Galecto Inc.
• GlaxoSmithKline Plc
• IOVANCE Biotherapeutics Inc.
• Johnson and Johnson
• Merck and Co. Inc.
• Moderna Inc.
• Novartis AG
• Parexel International Corp.
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• F. Hoffmann La Roche Ltd.
• Boehringer Ingelheim International GmbH.

Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed
annually at USD 5000

Lung Cancer Therapeutics Market – Therapy Outlook (Revenue, USD mn, 2022-2027)

• Targeted therapy – size and forecast 2022-2027
• Immunotherapy – size and forecast 2022-2027
• Chemotherapy – size and forecast 2022-2027

Lung Cancer Therapeutics Market – Type Outlook (Revenue, USD mn, 2022-2027)

• NSCLC – size and forecast 2022-2027

• SCLC – size and forecast 2022-2027

Lung Cancer Therapeutics Market – Geography Outlook (Revenue, USD mn, 2022-2027)

• North America – size and forecast 2022-2027

• Asia – size and forecast 2022-2027
• Europe – size and forecast 2022-2027
• Rest of World (ROW) – size and forecast 2022-2027

Learn about the contribution of each segment summarized in concise infographics and
thorough descriptions. View a PDF sample report

What are the key data covered in this lung cancer therapeutics market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the lung cancer therapeutics market between 2023 and 2027
• Precise estimation of the size of the lung cancer therapeutics market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the lung cancer therapeutics market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of lung cancer therapeutics market vendors

Related Reports

Non-small Cell Lung Cancer Drugs Market by Product and Geography – Forecast and Analysis 2022-2026: The increasing prevalence and incidence of non-small cell lung cancer are driving the market growth. This is because of the rise in risk factors such as cigarette smoking, secondary smoking, air pollution, and occupational exposure. In Asian countries, rapid industrial development, sub-urbanization, and disease patterns are leading to the increased prevalence of non-small cell lung cancer.

Throat Cancer Therapeutics Market by Type and Geography – Forecast and Analysis 2022-2026: The increasing incidence of throat cancer is driving the market growth. The global throat cancer therapeutics market has witnessed an increase in the number of new cases in recent years. Throat cancer is one of the most common types of cancer in many parts of Europe, Asia, and North America, with pharyngeal cancer being the dominant throat cancer indication, followed by laryngeal cancer.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global lung cancer therapeutics market 2017 – 2021
• Exhibit 18: Historic Market Size – Data Table on Global lung cancer therapeutics market 2017 – 2021 ($ million)

• 4.2 Therapy Segment Analysis 2017 – 2021 
• Exhibit 19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)

• 4.3 Type Segment Analysis 2017 – 2021 
• Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 – 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)

• 4.5 Country Segment Analysis 2017 – 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis – Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition – Five forces 2022 and 2027

6 Market Segmentation by Therapy

• 6.1 Market segments 
• Exhibit 30: Chart on Therapy – Market share 2022-2027 (%)
• Exhibit 31: Data Table on Therapy – Market share 2022-2027 (%)

• 6.2 Comparison by Therapy 
• Exhibit 32: Chart on Comparison by Therapy
• Exhibit 33: Data Table on Comparison by Therapy

• 6.3 Targeted therapy – Market size and forecast 2022-2027
• Exhibit 34: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)

• 6.4 Immunotherapy – Market size and forecast 2022-2027
• Exhibit 38: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)

• 6.5 Chemotherapy – Market size and forecast 2022-2027
• Exhibit 42: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Therapy 
• Exhibit 46: Market opportunity by Therapy ($ million)

7 Market Segmentation by Type

• 7.1 Market segments 
• Exhibit 47: Chart on Type – Market share 2022-2027 (%)
• Exhibit 48: Data Table on Type – Market share 2022-2027 (%)

• 7.2 Comparison by Type 
• Exhibit 49: Chart on Comparison by Type
• Exhibit 50: Data Table on Comparison by Type

• 7.3 NSCLC – Market size and forecast 2022-2027
• Exhibit 51: Chart on NSCLC – Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Data Table on NSCLC – Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Chart on NSCLC – Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on NSCLC – Year-over-year growth 2022-2027 (%)

• 7.4 SCLC – Market size and forecast 2022-2027
• Exhibit 55: Chart on SCLC – Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on SCLC – Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on SCLC – Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on SCLC – Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Type 
• Exhibit 59: Market opportunity by Type ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 61: Chart on Market share by geography 2022-2027 (%)
• Exhibit 62: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 63: Chart on Geographic comparison
• Exhibit 64: Data Table on Geographic comparison

• 9.3 North America – Market size and forecast 2022-2027
• Exhibit 65: Chart on North America – Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Data Table on North America – Market size and forecast 2022-2027 ($ million)
• Exhibit 67: Chart on North America – Year-over-year growth 2022-2027 (%)
• Exhibit 68: Data Table on North America – Year-over-year growth 2022-2027 (%)

• 9.4 Europe – Market size and forecast 2022-2027
• Exhibit 69: Chart on Europe – Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
• Exhibit 71: Chart on Europe – Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on Europe – Year-over-year growth 2022-2027 (%)

• 9.5 Asia – Market size and forecast 2022-2027
• Exhibit 73: Chart on Asia – Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on Asia – Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Asia – Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
• Exhibit 77: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)

• 9.7 US – Market size and forecast 2022-2027
• Exhibit 81: Chart on US – Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on US – Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on US – Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on US – Year-over-year growth 2022-2027 (%)

• 9.8 UK – Market size and forecast 2022-2027
• Exhibit 85: Chart on UK – Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on UK – Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on UK – Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on UK – Year-over-year growth 2022-2027 (%)

• 9.9 Canada – Market size and forecast 2022-2027
• Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)

• 9.10 China – Market size and forecast 2022-2027
• Exhibit 93: Chart on China – Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on China – Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on China – Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on China – Year-over-year growth 2022-2027 (%)

• 9.11 France – Market size and forecast 2022-2027
• Exhibit 97: Chart on France – Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on France – Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on France – Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on France – Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 101: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 102: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 103: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 104: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 105: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 106: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 107: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 108: AbbVie Inc. – Overview
• Exhibit 109: AbbVie Inc. – Product / Service
• Exhibit 110: AbbVie Inc. – Key offerings

• 12.4 Amgen Inc. 
• Exhibit 111: Amgen Inc. – Overview
• Exhibit 112: Amgen Inc. – Product / Service
• Exhibit 113: Amgen Inc. – Key offerings

• 12.5 Astellas Pharma Inc. 
• Exhibit 114: Astellas Pharma Inc. – Overview
• Exhibit 115: Astellas Pharma Inc. – Product / Service
• Exhibit 116: Astellas Pharma Inc. – Key news
• Exhibit 117: Astellas Pharma Inc. – Key offerings

• 12.6 AstraZeneca Plc 
• Exhibit 118: AstraZeneca Plc – Overview
• Exhibit 119: AstraZeneca Plc – Product / Service
• Exhibit 120: AstraZeneca Plc – Key news
• Exhibit 121: AstraZeneca Plc – Key offerings

• 12.7 Boehringer Ingelheim International GmbH
• Exhibit 122: Boehringer Ingelheim International GmbH – Overview
• Exhibit 123: Boehringer Ingelheim International GmbH – Business segments
• Exhibit 124: Boehringer Ingelheim International GmbH – Key news
• Exhibit 125: Boehringer Ingelheim International GmbH – Key offerings
• Exhibit 126: Boehringer Ingelheim International GmbH – Segment focus

• 12.8 Bristol Myers Squibb Co. 
• Exhibit 127: Bristol Myers Squibb Co. – Overview
• Exhibit 128: Bristol Myers Squibb Co. – Product / Service
• Exhibit 129: Bristol Myers Squibb Co. – Key offerings

• 12.9 Daiichi Sankyo Co. Ltd. 
• Exhibit 130: Daiichi Sankyo Co. Ltd. – Overview
• Exhibit 131: Daiichi Sankyo Co. Ltd. – Business segments
• Exhibit 132: Daiichi Sankyo Co. Ltd. – Key news
• Exhibit 133: Daiichi Sankyo Co. Ltd. – Key offerings
• Exhibit 134: Daiichi Sankyo Co. Ltd. – Segment focus

• 12.10 Eli Lilly and Co. 
• Exhibit 135: Eli Lilly and Co. – Overview
• Exhibit 136: Eli Lilly and Co. – Product / Service
• Exhibit 137: Eli Lilly and Co. – Key offerings

• 12.11 F. Hoffmann La Roche Ltd. 
• Exhibit 138: F. Hoffmann La Roche Ltd. – Overview
• Exhibit 139: F. Hoffmann La Roche Ltd. – Business segments
• Exhibit 140: F. Hoffmann La Roche Ltd. – Key news
• Exhibit 141: F. Hoffmann La Roche Ltd. – Key offerings
• Exhibit 142: F. Hoffmann La Roche Ltd. – Segment focus

• 12.12 GlaxoSmithKline Plc 
• Exhibit 143: GlaxoSmithKline Plc – Overview
• Exhibit 144: GlaxoSmithKline Plc – Business segments
• Exhibit 145: GlaxoSmithKline Plc – Key offerings
• Exhibit 146: GlaxoSmithKline Plc – Segment focus

• 12.13 Merck and Co. Inc. 
• Exhibit 147: Merck and Co. Inc. – Overview
• Exhibit 148: Merck and Co. Inc. – Business segments
• Exhibit 149: Merck and Co. Inc. – Key news
• Exhibit 150: Merck and Co. Inc. – Key offerings
• Exhibit 151: Merck and Co. Inc. – Segment focus

• 12.14 Novartis AG 
• Exhibit 152: Novartis AG – Overview
• Exhibit 153: Novartis AG – Business segments
• Exhibit 154: Novartis AG – Key offerings
• Exhibit 155: Novartis AG – Segment focus

• 12.15 Pfizer Inc. 
• Exhibit 156: Pfizer Inc. – Overview
• Exhibit 157: Pfizer Inc. – Product / Service
• Exhibit 158: Pfizer Inc. – Key news
• Exhibit 159: Pfizer Inc. – Key offerings

• 12.16 Sanofi SA 
• Exhibit 160: Sanofi SA – Overview
• Exhibit 161: Sanofi SA – Business segments
• Exhibit 162: Sanofi SA – Key news
• Exhibit 163: Sanofi SA – Key offerings
• Exhibit 164: Sanofi SA – Segment focus

• 12.17 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 165: Takeda Pharmaceutical Co. Ltd. – Overview
• Exhibit 166: Takeda Pharmaceutical Co. Ltd. – Product / Service
• Exhibit 167: Takeda Pharmaceutical Co. Ltd. – Key news
• Exhibit 168: Takeda Pharmaceutical Co. Ltd. – Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 169: Inclusions checklist
• Exhibit 170: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 171: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 172: Research methodology
• Exhibit 173: Validation techniques employed for market sizing
• Exhibit 174: Information sources

• 13.5 List of abbreviations 
• Exhibit 175: List of abbreviations

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/lung-cancer-therapeutics-market-size-to-grow-by-usd-10-204-33-million-high-prevalence-of-lung-cancer-remains-key-growth-driver—technavio-301696992.html

SOURCE Technavio

PR Newswire Science News